Sinan Ümit Yaşar, Demir Rengin, Canbolat İsmail Polat, Palabıyık Mert, Kaya Ayşem, Küçükoğlu Mehmet Serdar
Departments of Cardiology, İstanbul University Institute of Cardiology; İstanbul-Turkey.
Anatol J Cardiol. 2018 Jul;20(1):35-40. doi: 10.14744/AnatolJCardiol.2018.60252.
Pulmonary artery hypertension (PAH) is characterized by remodeling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance and right ventricular failure. In this study, we aimed to share our 10 years of experience dealing with pulmonary hypertension (PH) and provide information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a tertiary center.
In this retrospective, single-center, observational study, we screened the patients who applied to PH outpatient clinic of İstanbul University Institute of Cardiology due to the suspicion of PAH between 2008 and 2017. While group 1, 4, and 5 PH patients were included, group 2 and 3 PH patients were excluded from the study.
Our study group comprised 162 patients (115 females, 71%). The female:male ratio was 2.4. The mean age was 52±16 years. Most (86.4%) of the patients were in group 1 PH (PAH). The rest (13.6%, n=22) of the patients were in group 4 PH (chronic thromboembolic PH). In group 1 PH, 45.7% of patients (n=64) were classified as having idiopathic PAH (IPAH) after excluding the alternative diagnosis using PH diagnostic algorithm. The remaining 54.3% of group 1 PH patients (n=76) had various diseases that caused PAH, which is called associated PAH (APAH); APAH group included PAH associated with congenital heart diseases (n=70), connective tissue disorders (scleroderma, n=4) and portal hypertension (n=2).
Our data provides important information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a reference tertiary center in Turkey.
肺动脉高压(PAH)的特征是肺小动脉重塑,导致肺血管阻力逐渐增加和右心室衰竭。在本研究中,我们旨在分享我们处理肺动脉高压(PH)10年的经验,并在实际临床环境中提供关于三级中心PAH患者的人口统计学、临床病程、PH亚组分布和治疗模式的信息。
在这项回顾性、单中心、观察性研究中,我们筛选了2008年至2017年间因疑似PAH而到伊斯坦布尔大学心脏病学研究所PH门诊就诊的患者。纳入1、4和5组PH患者,排除2和3组PH患者。
我们的研究组包括162例患者(115例女性,占71%)。女性与男性比例为2.4。平均年龄为52±16岁。大多数患者(86.4%)属于1组PH(PAH)。其余患者(13.6%,n = 22)属于4组PH(慢性血栓栓塞性PH)。在1组PH中,45.7%的患者(n = 64)在使用PH诊断算法排除其他诊断后被分类为特发性PAH(IPAH)。1组PH的其余54.3%患者(n = 76)患有各种导致PAH的疾病,即相关性PAH(APAH);APAH组包括与先天性心脏病相关的PAH(n = 70)、结缔组织病(硬皮病,n = 4)和门静脉高压(n = 2)。
我们的数据在实际临床环境中提供了关于土耳其一家参考三级中心PAH患者的人口统计学、临床病程、PH亚组分布和治疗模式的重要信息。